Plasmapheresis Device Market
Plasmapheresis is a procedure in which blood is separated into cells and plasma (liquid). The plasma is then removed and replaced with fresh frozen plasma. It is done to treat variety of autoimmune disorders such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, sickle cell anemia, guillain-barre syndrome, and lambert- eaton myasthenic syndrome where autoantibodies are generated harming the body.
Plasmapheresis is a procedure in which blood is separated into cells and plasma (liquid). The plasma is then removed and replaced with fresh frozen plasma. It is done to treat variety of autoimmune disorders such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, sickle cell anemia, guillain-barre syndrome, and lambert- eaton myasthenic syndrome where autoantibodies are generated harming the body.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
REPORT DESCRIPTION<br />
<strong>Plasmapheresis</strong> <strong>Device</strong> <strong>Market</strong> – Overview<br />
For instance, on September 2018, Shire plc. (SHP) acquired sanaplasma AG, augmenting plasma collection<br />
network. The acquisition of sanaplasma AG is expected to increase Shire's access to plasma in the longer<br />
term and also widens its European plasma collection network, complementing existing core capabilities in<br />
plasma supply and manufacturing. This will also help to increase the customer base in the European region<br />
which in turn will raise demand for <strong>Plasmapheresis</strong> devices in the market.<br />
Moreover, Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest US<br />
Corporation, was acquired by Grifols Shared Services North America, Inc., in August 2018. This<br />
acquisition comprises 22 BPC plasma collection centers that manufactures critical care therapies to treat<br />
life threatening disorders. This acquisition of BPC will lead to increased availability of number of<br />
resources for plasma collections and likely to stimulate the growth of plasmapheresis devices in the global<br />
market.<br />
© Coherent market Insights. All Rights Reserved
Change language